Gilead results rise on improved product sales, easily beating estimates

Gilead Sciences' (GILD) Q4 sales growth was helped by higher sales of GILD's newer HIV drugs: Stribild sales totaled $203M, up from $40M a year earlier, and Complera sales were $262M, more than double last year's level.

Q4 Atripla sales +1.8% Y/Y to $933M, Truvada sales -2.2% Y/Y to $814M; antiviral product sales rose 22% to $2.64B, while cardiovascular product sales gained 25% to $268.5M.

Sales of the much anticipated new hepatitis C treatment Sovaldi totaled $139M in the final weeks of 2013, after winning FDA approval in early December.

Looking to 2014, GILD sees full-year sales of $11.3B-$11.5B, a view that excludes Sovaldi sales.

Shares flat AH after rising 4% during regular trading.

From other sites
Comments (7)
  • JT_N
    , contributor
    Comment (1) | Send Message
    I don't understand why this stock didn't jump...
    4 Feb 2014, 06:06 PM Reply Like
  • zondlo
    , contributor
    Comments (32) | Send Message
    Same here
    4 Feb 2014, 06:18 PM Reply Like
  • zondlo
    , contributor
    Comments (32) | Send Message
    That was a big beat !
    4 Feb 2014, 06:20 PM Reply Like
  • 3Tavgreg
    , contributor
    Comments (139) | Send Message
    It didn't jump because a lot of it was already priced in. That being said, I listened
    to most of the conference call, and there were a lot of congratulations going around.
    As there were no downside surprises, I think that $GILD will slowly melt up;(taking the macro market into account). As the market and analysts digest this qtr and positive
    guidance,(that didn't even include Suvaldi), I believe price targets will rise, grinding
    the stock price inevidentably higher. I am long $GILD.
    4 Feb 2014, 06:45 PM Reply Like
  • scotttoconnor
    , contributor
    Comment (1) | Send Message
    Baked in already....
    4 Feb 2014, 07:17 PM Reply Like
  • Kboyd78
    , contributor
    Comments (162) | Send Message
    You guys can bake whatever you want I'm buying as much if this stock as I can afford. That call was awesome they are changing how you treat diseases that used to be a death sentence. Ill invest with these people any day
    5 Feb 2014, 08:30 AM Reply Like
  • john edwin peterson
    , contributor
    Comments (347) | Send Message
    Can anyone name a company that has changed the way we deal with previously death sentence diseases. Who else would shell 11 billion on the hope they could find a cure for hep c This company is what free market capitalism is all about. The next time somebody says that America is losing their way and cannot compete on the world stage just say I am proud that we have these people at Gilead
    7 Feb 2014, 12:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs